Evidence map›Paper›PMID 42721374›Full record

ArticleOncoimmunology2026

Profiling tumor immune microenvironment of epithelial ovarian carcinoma.

Zeinab Dehghani-Ghobadi, Vasilis S Dionellis, Clara Traber, Jonathan S Moore, Nicolas Samartzis, Stephan Ryser, Dimitrios R Kalaitzopoulos, Nicolas Liaudet, Clothilde Ferreira, Valentine Du Bois and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zeinab Dehghani-GhobadiDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland.
Vasilis S DionellisDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland.ORCID 0000-0003-4404-4577
Clara TraberDepartment of Gynecology, University Hospital Zurich, Zurich, Switzerland.
Jonathan S MooreDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland.
Nicolas SamartzisDepartment of Gynecology, University Hospital Zurich, Zurich, Switzerland.
Stephan RyserDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland.
Dimitrios R KalaitzopoulosDepartment of Gynecology, University Hospital Zurich, Zurich, Switzerland.
Nicolas LiaudetBioimaging Core Facility, Faculty of Medicine, University of Geneva, Genève, Switzerland.
Clothilde FerreiraDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland.
Valentine Du BoisDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland.
Paula StanclDepartment of Biology, Faculty of Science, Bioinformatics Group, Division of Molecular Biology, University of Zagreb, Zagreb, Croatia.
Rosa KarlicDepartment of Biology, Faculty of Science, Bioinformatics Group, Division of Molecular Biology, University of Zagreb, Zagreb, Croatia.
Mathias ChoschzickDepartment of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
Aurelia NoskeDepartment of Pathology, Technische Universität München, Munich, Germany.
José L SandovalDepartment of Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland.
Eleftherios Pierre SamartzisDepartment of Gynecology, University Hospital Zurich, Zurich, Switzerland.ORCID 0000-0002-8246-5842
Intidhar Labidi-GalyDepartment of Medicine and Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland.ORCID 0000-0002-0824-3475

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpithelial ovarian carcinoma (EOC) comprises five main histological subtypes: high-grade serous (HGSOC), low-grade serous (LGSOC), clear cell (CCOC), mucinous (MOC), and endometrioid (ENOC). Each histotype harbors specific genomic alterations and clinical outcome. Few studies systematically compared the tumor immune microenvironment across the five subtypes.

methodsWe performed 7-plex (CD45, CD8, CD68, CD163, FoxP3, CD20, and cytokeratin) sequential immunohistochemistry on a clinically annotated tissue microarray including 139 EOC representing the five subtypes and 26 borderline tumors (serous and mucinous). Digital pathology was used to quantify immune cell abundance, their spatial distribution (stroma vs tumor core), and correlation with survival.

resultsImmune cells were dominated by macrophages and more abundant in the stroma than tumor core across the five subtypes, consistent with immune excluded pattern. Compared to HGSOC, CCOC displayed the highest infiltration by CD45

conclusionsEOC is characterized by histotype-specific immune milieux defined by macrophage dominance, epithelial immune exclusion and dynamic immune remodeling during progression from borderline tumors to invasive carcinomas.

Indexed as

Neoplasms, Glandular and EpithelialOvarian NeoplasmsTumor MicroenvironmentAntigens, CDBiomarkers, TumorCarcinoma, Ovarian EpithelialFemaleForkhead Transcription FactorsHumansImmunohistochemistryLymphocytes, Tumor-InfiltratingMacrophagesNeoplasm GradingTissue Array AnalysisAntigens, CDBiomarkers, TumorForkhead Transcription Factorsborderlineimmune profilingmultiplex immunohistochemistryOvarian cancertumor microenvironment

Identifiers

PMID42721374
PMCPMC13568574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.